Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters

Abstract To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS ΔcapB vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins ar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qingmei Jia, Helle Bielefeldt-Ohmann, Rachel M. Maison, Saša Masleša-Galić, Sarah K. Cooper, Richard A. Bowen, Marcus A. Horwitz
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e9a39705e2644b52ba89ce30a59b1a5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9a39705e2644b52ba89ce30a59b1a5e
record_format	dspace
spelling	oai:doaj.org-article:e9a39705e2644b52ba89ce30a59b1a5e2021-12-02T14:23:23ZReplicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters10.1038/s41541-021-00321-82059-0105https://doaj.org/article/e9a39705e2644b52ba89ce30a59b1a5e2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00321-8https://doaj.org/toc/2059-0105Abstract To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS ΔcapB vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins are constructed using the LVS ΔcapB vector, a highly attenuated replicating intracellular bacterium, and evaluated for efficacy in golden Syrian hamsters, which develop severe COVID-19-like disease. Hamsters immunized intradermally or intranasally with a vaccine co-expressing the Membrane and Nucleocapsid proteins and challenged 5 weeks later with a high dose of SARS-CoV-2 are protected against severe weight loss and lung pathology and show reduced viral loads in the oropharynx and lungs. Protection correlates with anti-Nucleocapsid antibody. This potent vaccine should be safe; inexpensive; easily manufactured, stored, and distributed; and given the high homology between Membrane and Nucleocapsid proteins of SARS-CoV and SARS-CoV-2, potentially serve as a universal vaccine against the SARS subset of pandemic causing β-coronaviruses.Qingmei JiaHelle Bielefeldt-OhmannRachel M. MaisonSaša Masleša-GalićSarah K. CooperRichard A. BowenMarcus A. HorwitzNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Qingmei Jia Helle Bielefeldt-Ohmann Rachel M. Maison Saša Masleša-Galić Sarah K. Cooper Richard A. Bowen Marcus A. Horwitz Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
description	Abstract To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS ΔcapB vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins are constructed using the LVS ΔcapB vector, a highly attenuated replicating intracellular bacterium, and evaluated for efficacy in golden Syrian hamsters, which develop severe COVID-19-like disease. Hamsters immunized intradermally or intranasally with a vaccine co-expressing the Membrane and Nucleocapsid proteins and challenged 5 weeks later with a high dose of SARS-CoV-2 are protected against severe weight loss and lung pathology and show reduced viral loads in the oropharynx and lungs. Protection correlates with anti-Nucleocapsid antibody. This potent vaccine should be safe; inexpensive; easily manufactured, stored, and distributed; and given the high homology between Membrane and Nucleocapsid proteins of SARS-CoV and SARS-CoV-2, potentially serve as a universal vaccine against the SARS subset of pandemic causing β-coronaviruses.
format	article
author	Qingmei Jia Helle Bielefeldt-Ohmann Rachel M. Maison Saša Masleša-Galić Sarah K. Cooper Richard A. Bowen Marcus A. Horwitz
author_facet	Qingmei Jia Helle Bielefeldt-Ohmann Rachel M. Maison Saša Masleša-Galić Sarah K. Cooper Richard A. Bowen Marcus A. Horwitz
author_sort	Qingmei Jia
title	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
title_short	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
title_full	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
title_fullStr	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
title_full_unstemmed	Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters
title_sort	replicating bacterium-vectored vaccine expressing sars-cov-2 membrane and nucleocapsid proteins protects against severe covid-19-like disease in hamsters
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e9a39705e2644b52ba89ce30a59b1a5e
work_keys_str_mv	AT qingmeijia replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters AT hellebielefeldtohmann replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters AT rachelmmaison replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters AT sasamaslesagalic replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters AT sarahkcooper replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters AT richardabowen replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters AT marcusahorwitz replicatingbacteriumvectoredvaccineexpressingsarscov2membraneandnucleocapsidproteinsprotectsagainstseverecovid19likediseaseinhamsters
_version_	1718391460390240256

Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters

Ejemplares similares